Analyzing Prime Medicine (NYSE:PRME) & PharmaCyte Biotech (OTCMKTS:PMCBD)

PharmaCyte Biotech (OTCMKTS:PMCBD) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility and Risk

PharmaCyte Biotech has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.55, indicating that its stock price is 155% more volatile than the S&P 500.

Insider & Institutional Ownership

0.0% of PharmaCyte Biotech shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 22.7% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares PharmaCyte Biotech and Prime Medicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PharmaCyte Biotech	N/A	-49.09%	-43.39%
Prime Medicine	N/A	-107.87%	-74.97%

Earnings & Valuation

This table compares PharmaCyte Biotech and Prime Medicine”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A
Prime Medicine	$4.63 million	149.29	-$198.13 million	($1.35)	-2.84

PharmaCyte Biotech has higher earnings, but lower revenue than Prime Medicine.

Analyst Ratings

This is a breakdown of recent ratings and price targets for PharmaCyte Biotech and Prime Medicine, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PharmaCyte Biotech	0	0	0	0	0.00
Prime Medicine	0	3	4	0	2.57

Prime Medicine has a consensus price target of $7.21, indicating a potential upside of 88.21%. Given Prime Medicine’s stronger consensus rating and higher probable upside, analysts plainly believe Prime Medicine is more favorable than PharmaCyte Biotech.

Summary

Prime Medicine beats PharmaCyte Biotech on 7 of the 10 factors compared between the two stocks.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

About Prime Medicine

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.